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 INTRODUCTION 
Tablets may be defined as solid pharmaceutical dosage forms containing drug substances with or 
without suitable diluents and prepared either by compression or molding methods. They have 
been in widespread use since the latter part of 19th century and their popularity continues. The 
term compressed tablet is believed to have been first used by 'John Wyeth and Philadelphinn'. 
During the same period molded tablets were introduced to be used as Hypodermic tablets for 
injections. 
Tablets remain popular as a dosage form because of the advantages, afforded both to the 
manufacturer[eg. simplicity & economy of preparation, stability and convenience in packing, 
shipping, and dispensing]  and the patient[eg .accuracy of dosage, compactness, poor  stability, 
blendness of taste and ease of administration]. 
Although tablets are more frequently discoid in shape, they also may be round, oval, oblong, 
cylindrical or triangular. They may differ greatly in size and weight depending on the amount of 
drug substance present and the intended method of administration.
 
Tableting Formulations
1
 : 
In the tablet- pressing process, it is important that all ingredients be fairly dry, powdered or 
granular, somewhat uniform in practice size, and freely flowing. Mixed partical sieved powders 
can segregate during manufacturing operations due to different densities, which can result in 
tablets with poor drug or active pharmaceutical ingredients(API) content uniformity but 
granulation should prevent this. Content uniformity ensures that the same API dose is delivered 
with each tablet. 
Some API  may be  as tabletted pure substances, But this is rarely the case; most formulations 
include excipients. Normally, an pharmacologically inactive ingredient(excipient) termed a 
binder is added it help hold the tablet together and give is strength. A wide variety of binders 
may be used, some common ones including lactose, dibasic calcium phosphate, sucrose, corn, 
maize, starch, microcrystalline cellulose and modified cellulose(for eg. hydroxypropyl methyl 
cellulose) ingredient is also needed to act as a disintegrate to aid tablet dispersion once 
swallowed, releasing the API for absorption. Some binders, such as starch and cellulose, are also 
excellent disintegrants. 
 
Small amounts of lubricants are usually added as well. The most common of these is magnesium 
sterate; however, other commonly used tablet lubricants include stearic acid, stearin, 
hydrogenated oil, and sodium stearyl fumarate. These help the tablets once pressed, to be more 
easily ejected from the Die. 
Types of Tablets: 
Tablets are classified according to their route of administration or function. The following are the 
4 main classification groups: 
 
1. Tablets ingested orally 
 
 a) Compressed tablets. 
 
` b) Multiple compressed tablets. 
 
 c) Multi layered tablets. 
 
 d) Sustained action tablets. 
 
 e) Enteric coated tablets. 
 
 f) Sugar coated tablets. 
 
 g) Film coated tablets. 
 
 h) Chewable tablets. 
 
 
 
 
 
 
 2. Tablets used in the oral cavity, Buccal tablets 
 
 a) Sublingual tablets .  
 
 b) Lozenge tablets and torches . 
 
 c) Dental cones. 
3. Tablets administered by other routes 
 
 a) Implantation tablets . 
 
 b) vaginal tablets . 
 
4. Tablets used to prepare solutions 
 
 a) Effervescent tablets, Molded tablets or tablet triturates(TT) 
 
 b) Dispersible tablets(DT) 
 
 c) Hypodermic tablets(HT) 
 
Compressed tablets : 
These tablets are uncoated and made by compression granules. These tablets are usually intended 
to provide rapid disintegration and drug release. These tablets contain water-soluble drugs, 
Which after swallowing get disintegrated in the stomach,  and its drug contents are absorbed in 
the gastrointestinal tract and distribute in the whole body. 
 
 
 
 
Multiple compressed tablets: 
These tablets are prepared to separate physically or chemically incompatible ingredients or to 
produce repeated action prolonged action products. To avoid incompatibility, the ingredients of 
the formation except the incompatible materials are compressed into a tablet then incompatible 
substance along with necessary excipients are compressed in to a tablet. 
Multi layered tablets: 
These tablets contains of two or more layers of compressed successively in the same tablet. The 
color of each layer may be the same or different. The tablets having layers of different colors are 
known as "multicolored tablets". 
Method of preparation of granules and tablets: 
The manufacture of granulation of tablet compression may follow one or a combination of 3 
established methods: 
Direct compression: 
In  direct compression method the raw materials are size reduced and the required excipients are 
added and directly compressed. A few crystalline substances can be directly compressed into 
tablets. Tablets development of lower strength drugs may follow two processes either by 
traditional alcoholic or aqueous wet granulation technique or via the simple direct compression 
mode with marginally faster dissolution rates. Dosage strength with 1-10 mg per 100 or 150 mg 
tablet is considered suitable drug candidates for direct compression. 
Wet granulation: 
This is Most widely used ant the mist general methods of the tablet preparation. Its popularity is 
due to the greater possibility that granules will meet all physical requirements for the 
compression of good tablets. Most powders cannot be compresses directly into tablets because  
the lack of proper characteristics of binding or together into a compact entity. The donor 
processes ordinarily lubricated and disintegrating properties. Wet granulation is the process in 
which the liquid is added to powder equipped with any type of agitation that will produce 
agglomeration or granules. 
Dry granulation: 
It is a valuable technique in situations where effective dose of  a drug is too high for direct 
compression, and the drug is sensitive to  heat, moisture, or both, which included wet 
granulation. This method involves the compaction of the components of a tablet formation by 
means of a tablet press or specially designed machinery, followed by milling and screening, prior 
to final compression into tablet. When the initial blend of   powders forced is  into dies of large 
capacity tablet press and is compacted by means of flat faced punches, the compacted masses are 
called "slugs" and the process is referred to as "slugging". On a  large scale, "Compression 
granulation". 
Excipients used in tablet formation: 
Excipient means any component other than active pharmaceutical ingredient(s) intentionally 
added to the formation of a dosage form. Many guidelines exist to aid in selection of nontoxic 
excipients such as IIG(Inactive Ingredient Guide), GRAS(Generally Regarded as Safe). 
Handbook of pharmaceutical Excipients and other. While selecting excipients for any 
formulation following things should be considered wherever possible: 
keep the excipients to a minimum in number, minimize the quantity of each excipient and 
multifunctional excipients may be given preference unifunctional excipients. Excipients play a 
crucial role in design of the delivery system, determining its quantity and performance. 
Excipients though usually regarded as nontoxic there are examples of known excipient induced 
toxicities which include renal failure and death from diethylene glycol, osmotic diarrhoea caused 
by ingested mannitol, hypersensitivity reactions from lanolin and cardiotoxicity induced by 
propylene glycol. 
 
 INTRODUCTION
2 
 Oral drug delivery has been known for decades as the most widely utilized route of 
administration among all the routes that has been explored for the systemic delivery of drugs via 
various pharmaceutical products of different dosage form. Now-a-days most of the 
pharmaceutical scientists are involved in developing an ideal DDS. This ideal system should 
have advantage of single dose for whole duration of the treatment and it should deliver the drug 
directly at specific site. Scientists have succeeded to develop a system that can be as near to an 
ideal system and it encourages the scientists to develop controlled release system. 
 FIG:1 Plot Between Drug Release Level & Time 
The design of oral sustain drug delivery system should be primarily aimed to achieve the 
more predictability and reproducibility to control the drug release, drug concentration in the 
target tissue and optimization of the therapeutic effect of a drug by controlling its release in the 
body with lower and less frequent dose. 
Conventional drug therapy typically involves the periodic dosing of a therapeutic agent 
that has been formulated in a manner to ensure its stability, activity and bioavailability. For most 
of the drugs, conventional methods of formulation are quite effective. However some drugs are 
unstable and toxic and have a narrow therapeutic range, exhibit extreme solubility problems, 
require localization to a particular site in the body or require strict compliance or long-term use. 
In such cases a method of continuous administration of drug is desirable to maintain fixed 
plasma drug levels.The goal in designing  sustained delivery systems is to reduce the frequency 
of the dosing or to increase effectiveness of the drug by localization at the site of action, reducing 
the dose required or providing uniform drug delivery. So, sustained release dosage form is a 
dosage form that release one or more drugs continuously in a predetermined pattern for a fixed 
period of time, either systemically or to a specified target organ. Sustained release dosage forms 
provide a better control of plasma drug levels, less dosage frequency, less side effect, increased 
efficacy and constant deliver 
Classification modified release drug delivery system: 
 A.Delayed release. 
 B.  Sustained release  
                Controlled release.  
                Extended release. 
C)Site specific targeting  
D)Receptor targeting 
A) Delayed Release:These systems are those that use repetitive, intermittent dosing of a drug 
from one or more immediate release units incorporated into a single dosage form.         
Examples of delayed release systems include repeat action tablets and capsules and enteric-
coated tablets where timed release is achieved by a barrier coating. 
B) Sustained release: During the last two decades there has been remarkable increase in 
interest in sustained release drug delivery system. This has been due to various factor such as 
the prohibitive cost of developing new drug entities, expiration of existing international 
patents, discovery of new polymeric materials  suitable for prolonging the drug release, and 
the improvement in therapeutic efficiency and safety achieved by these delivery systems. 
Now-a-days the technology of sustained release is also being applied to veterinary products. 
These systems also provide a slow release of drug over an extended period of time and also 
can provide some control, whether this be of a temporal or spatial nature, or both, of drug 
release in the body, or in other words, the system is successful at maintaining constant drug 
levels in the target tissue or cells. 
Controlled release: These system include any pharmaceutical dosage forms that achieves slow 
release of  drug over an extended period of time. 
 2) Extended Release:The system include any pharmaceutical dosage forms that release the drug 
slower than normal manner at predetermined rate & necessarily reduce the dosage frequency by 
two folds. 
C) Site specific targeting:These system refers, targeting a drug directly to a certain biological 
location. In this case the target is adjacent to or in the diseased organ or tissue. 
D) Receptor targeting:These system refer, targeting of a drug directly to a certain biological 
location. In this case the target is the particular receptor for a drug within an organ or tissue. Site 
specific targeting and receptor targeting systems satisfy the special aspect of drug delivery and 
are also considered to be sustained drug delivery systems. 
Potential advantages and disadvantages of sustained release dosage forms 
Advantages: 
 Avoid patient compliance problems. 
 Minimize or eliminate local side effects. 
 Minimize or eliminate systemic side effects.   
 Obtain less potentiation or reduction in drug activity with chronic use.             
 Minimize drug accumulation with chronic dosing.  
 Improve efficiency in treatment.  
 Cure or control condition more promptly.   
  Reduction in  fluctuation of  blood  drug level.  
 Improve bioavailability of some drugs.    
 Make use of special effects, e.g. sustained-release aspirin for morning relief of arthritis by 
dosing before bedtime. 
 SR drug delivery system aims at optimized therapy constant blood levels. 
 Constant blood levels achieved with  desired effect and this effect is maintained for an 
intended period of time. 
 Drugs susceptible to enzymatic inactivation or by bacterial decomposition can be protected 
by encapsulation in polymer system suitable for SR. 
 For drugs having specific window for absorption increased bioavailability can be attained by 
localizing the SR in that particular region of the GIT.  
 Economy  
DISADVANTAGES OF SUSTAINED RELEASE DOSAGE FORMS: 
 They are costly. Increased variability among dosage units 
 Dose dumping 
Challenges: Dose dumping:Dose dumping is a phenomenon where by relatively large quantities 
of drug in a sustained release formulation is rapidly released, introducing potential toxic 
quantities of the drug into the systemic circulation. Dose dumping can lead to   facialities in case 
of potent drug, which have a narrow therapeutic index.                                                                                      
                                     eg; Phenobarbital. 
Limited choice of selecting desired dose in the unit. In conventional dosage forms, dose 
adjustments are much simpler e.g. tablet can be divided into two fractions. In case of sustained 
release dosage forms, this appears to be much more complicated. Sustained release property may 
get lost, if dosage form is fractured. 
 Poor In- Vitro In - Vivo correlation: 
      In sustained release dosage form, the rate of drug release is deliberately reduced to achieve 
drug release possibly over a large region of gastrointestinal tract. Here so called 
‘Absorptionwindow’ becomes important and may give rise to un-satisfactory drug absorption 
in in-vivo despite excellent in in-vitro release. 
Patient variation 
      The time period required for absorption of drug, released from the dosage form may vary 
among individuals. Co-administration of other drugs, presence or absence of food and 
residence time in gastrointestinal tract is different among patients. This also gives rise to 
variation in clinical response among the patient. 
Criteria to be met by drug proposed to be formulated in sustained release dosage forms. 
a) Desirable half-life. 
b) High therapeutic index 
c) Small dose 
d) Desirable absorption and solubility characteristics. 
e) Desirable absorption window. 
f) First pass clearance 
 
 
 
\ 
 
 
 
 
 
 
 
 
 Floating drug delivery system  
1. Single unit floating dosage form  
  a. Non-effervescent systems: 
5,11 
The most commonly used excipients in non-effervescent FDDS are gel forming or highly 
swellable cellulose type hydrocolloids, polysaccharides and matrix forming polymers such as 
polycarbonate, polyacrylate, polymethacrylate and polystyrene., which swells in contact with 
gastric fluids after oral administration and maintains a relatve integrity of shape, bulk density of 
less than unity. The air entrapped by the swollen polymer confers buoyancy to these dosage 
forms.   
  i. Colloidal gel barrier system: 
11
This system incorporates a high level (20-75%w/w) of 
one or more gel-forming, highly swellable, cellulose type hydrocolloids (e.g. Hydroxy ethyl 
cellulose, hydroxy propyl cellulose, hydroxy propyl methyl cellulose , sodium carboxymethyl 
cellulose) polysaccharides and matrix forming polymers such as polycarbophil, polyacrylates 
and polystyrene, incorporated either in tablets or in capsules. When coming in contact with 
gastric fluid, the hydrocolloid in the system hydrates and form colloidal gel barrier around its 
surface. This gel-barrier control the rate of fluid penetration into the device and consequent 
release of the drug. As the exterior surface of the dosage form goes into the solution, the gel 
layer is maintained by the adjacent hydrocolloid layer becoming hydrated. The air trapped in by 
the swollen polymer maintains a density less than unity and confers buoyancy to these dosage 
forms.   
The HBS must comply with 3 major criteria:  
1) It must have sufficient structure to form a cohesive gel barrier.  
2) It must maintain an overall specific density lower than that of gastric contents.  
3) It should dissolve slowly enough to serve as a reservoir for the delivery system.  
 A bilayer tablet can also be prepared to contain one immediate-release and sustained 
release layer. Immediate-release layer delivers the initial dose, whereas SR layer absorbs gastric 
fluid and forms a colloidal gel barrier on its surface. This results in a system with bulk density 
lesser than that of the gastric fluid, and allows it to remain buoyant in stomach for an extended 
period of time.  
 
 ii. Microporouscompartmentsystem:                                                     
 This technology is based on the encapsulation of a drug reservoir inside a microporous 
compartment with apertures along its top and bottom walls. The peripheral wall of the drug 
reservoir compartment is completely sealed to prevent any direct contact of gastric mucosal 
surface with the un-dissolved drug. In stomach, the floatation chamber containing entrapped air 
causes the delivery system to float over the apertures, dissolves the drug and carries the dissolved 
drug for continuous transport across the intestine for absorption.   
b. Effervescent systems:
11 
 
A drug delivery system can be made to float in the stomach by incorporating a floating 
chamber, which may be filled with vaccum, air or inert gas. The gas in the floating chamber can 
be introduced either by the volatilization of an organic solvent or by the effervescent reaction 
between organic acids and bicarbonate salts.   
 i. Volatile liquid containing systems:
11 
 
The GRT of a drug delivery system can be sustained by incorporating an inflatable 
chamber which contains a liquid e.g. ether, cyclopentane that gasifies at body temperature to 
cause the inflatation of the chamber in the stomach. These devices are osmotically controlled 
floating systems containing a hollow deformable unit that can convert from a collapsed to an 
expanded position and returns to collapsed position after an extended period. The deformable 
system consists of two chambers separated by an impermeable, pressure-responsive, movable 
bladder. The first chamber contains the volatile liquid. The device inflates and the drug is 
continuously released from the reservoir into the gastric fluid. The device may also consists of a 
bioerodible plug made up of PVA, polyethylene etc. that gradually dissolves causing the 
inflatable chamber to release gas and collapse after a predetermined time to permit spontaneous 
ejection of the inflatable system from the stomach.  
 ii. Gas-generating systems : 
6,11 
 
These buoyant systems use matrices prepared with swellable polymers like HPMC, 
polysaccharides like chitosan, effervescent components like sodium bicarbonate, citric acid, 
tartaric acid, Di-sodium glycine carbonate, citroglycine etc. The optimal stoichiometric ratio of 
citric acid and sodium bicarbonate for gas generation is reported to be 0.76:1. Effervescent 
reaction between bicarbonate salts and citric acid/tartaric acid liberates CO
2
,which gets 
entrapped in the gellified hydrocolloid layer of the system, thus decreasing its specific gravity 
and making it to float over chyme. These tablets may be either single layered wherein the 
carbondioxide generating components are intimately mixed within the tablet matrix, or they may 
be bilayered in which the gas generating components are compressed in hydrocolloid containing 
layer and the drug in other layer formulated for a SR effect.   
2. Multiple unit floating dosage form  
a. Non-effervescent system  
i. Alginate beads:
 11
 Spherical beads of approximately 2.5mm in diameter can be prepared by 
dropping a sodium alginate solution into aqueous solution of calcium alginate. The beads are 
then separated, snap frozen in liquid nitrogen and freeze-dried at 40
0
c for 24 hours, leading to the 
formation of a porous system, which can maintain a floating force for 12 hours.  
ii. Hollow microspheres:
 6
 Hollow microspheres are considered as one of the most promising 
buoyant systems as they possess the unique advantages of multiple unit systems as well as better 
floating properties, because of the central hollow space inside the microsphere. The general 
techniques involved in their preparation include simple solvent evaporation and solvent diffusion 
and evaporation. Polymers such as polycarbonate, eudragit S and cellulose acetate are used in the 
preparation of hollow microspheres and the drug release can be modified by optimizing the 
amount of polymer-plasticizer ratio. Hollow microspheres floated with drug in their outer 
polymer shelf can also be prepared by a novel emulsion solvent-diffusion method. The 
ethanol/dichloromethane solution of the drug and an enteric acrylic polymer was poured into an 
agitated solution of poly vinyl alcohol that was thermally controlled at 40
0
C. The gas phase is 
generated in the dispersed polymer droplet by the evaporation of dichloromethane formed an 
internal cavity in the microsphere of the polymer with drug. The microballoon floated 
continuously over the surface of an acidic dissolution media containing surfactant for more than 
12 hours.  
b. Gas-generating systems: 
11 
Multi unit types of floating pills, which generate CO2 have also 
been developed. The system consists of a SR pill as seed, surrounded by double layers. The inner 
layer is an effervescent layer containing sodium bicarbonate and tartaric acid. When the system 
is immersed in buffer solution at 37
0
C swollen pills, like balloons are formed having density less 
than 1g/ml. This occurs due to CO2 neutralization of the inner effervescent layer with the 
diffusion of water through the outer swellable membrane layer. These kinds of systems float 
completely within 10min and remain floating over extended periods of 5-6 hours.   
c. Ion-exchange resin system: 
5
The system consisted of resin beads, which were loaded with the 
bicarbonate and a negatively charged drug that was bound to the resin. The resultant beads were 
then encapsulated in a semipermeable membrane to overcome rapid loss of CO2. Upon arrival in 
the acidic environment of stomach, an exchange of chloride and bicarbonate ions took place. As 
a result of this reaction, carbondioxide was released and trapped in the membrane, thereby 
carrying beads towards the top of gastric contents and producing a floating layer of resin beads.   
Bio/Mucoadhesive systems
2
 
Bioadhesive drug delivery systems (BDDS) are useful as a delivery device within the lumen to 
enhance drug absorption in a site-specific manner. This approach involves the use of bioadhesive 
polymers, which can adhere to the epithelial surface in the stomach. Gastric mucoadhesion does 
not tend to be strong enough to impart the dosage forms the ability to resist the strong propulsion 
forces of the stomach wall. The continuous production of mucous that is lost through peristalitic 
contractions and the dilution of the stomach contents also seem to limit the potential of 
mucoadhesion as a gastroretentive force. Some of the most promising excipients that have been 
used commonly in these systems include polycarbophil, carbopol, lectins, chitosan and gliadin 
etc. The adhesion of the polymers with the mucous membrane may be mediated by hydration, 
bonding or receptor mediated. 
 
Swelling systems
3  
Swelling systems are also referred to as plug type systems. The presence of polymers in the 
systems promotes their swelling to a size that prevents their passage through pyloric sphincter 
resulting in prolonged GRT. However, a balance between the rate and extent of swelling and the 
rate of erosion of the polymer is crucial to achieve optimum benefits and to avoid unwanted side 
effect 
High density system
12
 
 
This approach involves formulation of dosage forms with the density that must exceed density of 
normal stomach content (1.004g/cm3). These formulations are prepared by coating drug on a 
heavy core or mixed with heavy inert materials such as iron powder, zinc oxide, titanium dioxide 
or barium sulphate. These resultant pellets can be coated with diffusion controlled membrane. 
These systems with a density of about 3g/cm3 are retained in the rugae of the stomach and are 
capable of withstanding its peristalitic movements. 2.6-2.8g/cm
3
 acts as a threshold density after 
which such systems can be retained in the lower part of the stomach. 
 
Expansive gastroretentive dosage form
12
 
This is a class of gastroretentive systems capable of expanding in stomach. The expanded 
structure is trapped in stomach for prolonged period leading to sustained drug release and 
subsequent controlled absorption in stomach and intestine. These systems are administered 
perorally in the form of capsule bearing the dosage form in folded and compact configuration. 
When exposed to gastric environment capsule shell breaks and the dosage form attains its 
expanded structure, which is retained in stomach for longer time.  
Raft forming systems
3, 4
 
Raft forming systems have received much attention for the delivery of antacids and drug delivery 
for gastrointestinal infections and other disorders. The mechanism involved in the raft formation 
includes the formation of a viscous cohesive gel in contact with gastric fluids, wherein each 
portion of the liquid swells forming a continuous layer called a raft. This raft floats on gastric 
fluids because of the low bulk density created by the formation of CO2. Usually, the system 
contains a gel forming agents and alkaline bicarbonates or carbonates responsible for the 
formation of CO2 to make the system less dense and able to float on the gastric fluids. This 
floating rafts impedes the reflux of acids and food by acting as a physical barrier. The raft has a 
pH value higher than that of the stomach contents so that in the event of gastric reflux, the wall 
of the esophagus is not subjected to irritation by HCl.   
Suitable drug candidates for gastroretention.
4
 
In general, appropriate candidates for CR-GRDF are molecules that have poor colonic absorption 
but are characterized by better absorption properties at the upper parts of the GIT: 
 
 Narrow absorption window in GI tract, e.g. Riboflavin and Levodopa.  
 Primarily absorbed from stomach and upper part of GI tract e.g. Calcium.  
           supplements, Chlorodiazepoxide and Cinnarazine.  
 Drugs that act locally in the stomach e.g. Antacids and Misoprostol. 
 Drugs that degrade in the colon e.g. Ranitidine HCl and Metronidazole.  
 Drugs that disturb normal colonic bacteria, e.g. Amoxicillin trihydrate.  
 
 
 Factors affecting floating drug delivery system
3,5,7 
1. Density of dosage form: Dosage forms having a density lower than that of gastric fluid 
experience floating behavior and hence gastric retention. Density <1.0g/cm
3
 is required to exhibit 
floating property.  
 
 
2. Size of dosage form: The size of the dosage form is another factor that influences gastric 
retention .The mean gastric residence times of non-floating dosage forms are highly variable and 
greatly dependent on their size, which may be small, medium and large units. In fed conditions, 
the smaller units get emptied from the stomach during the digestive phase and the larger units 
during the house keeping waves. In most cases, the larger the size of the dosage form the greater 
will be the gastric retention time because the larger size would not allow the dosage form to 
quickly pass through the pyloric sphincter into the intestine. Dosage form units with a diameter 
more than 7.5mm are reported to increase GRT compared with those with diameter of 9.9mm. 
   
3. Food intake and nature of food: Food intake, the nature of the food, caloric content and 
frequency of feeding has a profound effect on the gastric retention of dosage forms. The presence 
or absence of food in the stomach influences the GRT of the dosage forms. Usually, the presence 
of food increases the GRT of the dosage form and increases drug absorption by allowing it to 
stay at the absorption site for a longer time. Usually fats tend to form an oily layer on the other 
gastric contents. As such, fatty substances are emptied later than other. Also, increased acidity 
and osmolality slow down gastric emptying.   
 
4. Stress: stress appears to cause an increase in gastric emptying rate, while depression slows it 
down.     
 
5. Shape: Tetrahedron and ring-shaped devices with a flexural modulus of 48 and 22.5 kilo 
pounds per square inch (KSI) are reported to exhibit a better GRT and 90%-100% retention at 
24hour compared with other shapes. 
6. Concomitant drug administration: Anticholinergics like atropine and propantheline, opiates 
like codeine and prokinetic agents like metoclopramide and cisapride affect the FDDS.  
7. Sex: women and elderly have a slower gastric emptying rate than men and young people 
respectively.   
8. Posture: In a comparative study in humans by Gansbeke et al; the floating and non-floating 
systems behaved differently. In the upright position, the floating systems floated to the top of the 
gastric contents and remained for a longer time, showing prolonged GRT. But the non-floating 
units settled to the lower part of the stomach and underwent faster emptying as a result of 
peristaltic contractions and the floating units remained away from the pylorus. However, in 
supine position, the floating units are emptied faster than non-floating units of similar size. A 
study by Mojaverian et al., showed that effect of posture on GRT found no significant difference 
in mean GRT for individuals in upright, ambulatory and supine state.   
9. Shape: Tetrahedron and ring-shaped devices with a flexural modulus of 48 and 22.5 kilo 
pounds per square inch (KSI) are reported to exhibit a better GRT and 90%-100% retention at 
24hour compared with other shapes . 
10. Concomitant drug administration: Anticholinergics like Atropine and Propantheline, 
opiates like Codeine and prokinetic agents like Metoclopramide and Cisapride affect the FDDS    
11. Biological factors: Diabetes and crohn's disease also affect the FDDS.  
Advantages of gastro retentive drug delivery system
4,7
  
1. Enhanced bioavailability: The bioavailability of Riboflavin CR-GRDF is significantly 
enhanced in comparison to the administration of non-GRDF CR polymeric formulation.   
2. Enhanced first-pass biotransformation: In a similar fashion to the increased efficacy of 
active transporters exhibiting capacity limited activity, the pre-systemic metabolism of the tested 
compound may be considerably increased when the drug is presented to the metabolic enymes 
(Cytochrome P450, in particular CYP3A4) in a sustained manner, rather than by a bolus input.   
3. Sustained drug delivery/ reduced frequency of dosing: For drug with relatively short 
biological half-life, sustained and slow input from CR-GRDF may result in a flip-flop 
pharmacokinetics and enable reduced dosing frequency. This feature is associated with improved 
patient compliance and thereby improves therapy.   
4. Targeted therapy for local ailments in the upper GIT: The prolonged and sustained 
administration of the drug from GRDF to the stomach may be advantageous for local therapy in 
the stomach and small intestine as in the case of H.pylori induced peptic ulcer.   
5. Reduced fluctuations of drug concentration: Continuous input of the drug following CR-
GRDF administration produces blood drug concentrations within a narrow range compared to the 
immediate release dosage forms. Thus, fluctuations in drug effects are minimized and 
concentration dependent adverse effects that are associated with peak concentrations can be 
prevented. This feature is of special importance for drugs with a narrow therapeutic index.   
6. Extended time over critical (effective) concentration: The sustained mode of administration 
enables extension of the time over a critical concentration and thus enhances the 
pharmacological effects and improves the clinical outcomes.   
7. Site specific drug delivery: A floating dosage form is a feasible approach for drugs which 
have limited absorption sites in upper small intestine  
8. Minimized adverse activity at the colon: Retention of the drug in the GRDF at the stomach 
minimizes the amount of drug that reaches the colon. Thus, undesirable activities of drug in the 
colon may be prevented as in the case of β-lactam antibiotics.   
9. Administration of a prolonged release floating dosage form tablets or capsules will result in 
dissolution of the drug in gastric fluid. After emptying of the stomach contents, the dissolved 
drug available is for absorption in the small intestine. It is therefore expected that a drug will be 
fully absorbed from the floating dosage form if it remains in solution form even at alkaline pH of 
the intestine.   
10. When there is vigorous intestinal movement and a short transit time as might occur in certain 
type of diarrhea, poor absorption is expected under such circumstances and it may be 
advantageous to keep the drug in floating condition in stomach to get a relatively better response.   
11. Many drugs categorized as once-a-day delivery have been demonstrated to have suboptimal 
absorption due to dependence on the transit time of the dosage form making traditional extended 
release development challenging. Therefore, a system designed for longer gastric retention will 
extend the time within which drug absorption can occur in small intestine.   
Limitations of Floating drug delivery system
11,12
 
1. They require a sufficiently high level of fluids in the stomach, for enabling the system to float 
and to work efficiently. This limitation can be over whelmed by coating the dosage form with 
bioadhesive polymer or alternatively by prescribing the dosage form to be taken up with a glass 
full of water (200-250ml).  
 
2. FDDS are not suitable candidates for drugs with stability or solubility problem in stomach.   
3. Some drugs like nifedipine, which is well absorbed along the entire GI tract and undergoes 
extensive first pass metabolism may not be suitable for FDDS as the slow gastric emptying limits 
the systemic bioavailability.   
4. Drugs with irritant effect on gastric mucosa also limit the  applicability of FDDS.   
5. In case of bioadhesive systems, which form electrostatic and hydrogen bonds with the mucus, 
the acidic environment and the thick mucus prevent the bond formation at the mucus polymer 
interface. High turnover rate of the mucus may further aggravate the problem. 
6. For swellable systems, the maintenance of their size larger than the aperture of resting pylorus 
for required period of time is the major rate limiting factor. 
7. Above all, any dosage form designed to stay in stomach during the fasting state should be 
capable of resisting the house keeper waves of phase-III contractions of MMC.   
Applications of floating drug delivery systems
6,8
  
1. Sustained drug delivery: HBS systems can remain in the stomach for long periods and hence 
can release the drug over a prolonged period of time. The problem of short gastric residence time 
encountered with an oral CR formulation hence can be overcome with these systems. These 
systems have a bulk density of less than1 as a result of which they can float on the gastric 
contents. These systems are relatively large in size and passing from the pyloric opening is 
prohibited.  Recently sustained release floating capsules of nicardipine hydrochloride were 
developed and were evaluated in vivo. The formulation compared with commercially available 
MICARD capsules using rabbits. Plasma concentration time curves showed a longer duration for 
administration (16hours) in the sustained release floating capsules as compared with 
conventional MICARD capsules (8hours).  
2. Site-specific drug delivery: These systems are particularly advantageous for drugs that are 
specifically absorbed from stomach or the proximal part of the small intestine e.g. Riboflavin and 
Furosemide. A bilayer-floating capsule was developed for local delivery of Misoprostol, which is 
a synthetic analog of prostaglandin E1 used as a protectant of gastric ulcers caused by 
administration of NSAIDs. By targeting slow delivery of misoprostol to the stomach, desired 
therapeutic levels could be achieved and drug waste could be reduced.  
3. Absorption enhancement: Drugs that have poor bioavailability because of site-specific 
absorption from the upper part of the gastrointestinal tract are potential candidates to be 
formulated as floating drug delivery systems, there by maximizing their absorption.  A 
significant increase in the bioavailability of floating dosage forms (42.9%) could be achieved as 
compared with commercially available LASIX tablets (33.4%) and enteric coated LASIX-long 
product (29.5%).  
4. Medopar HBS – containing L-dopa and benserazide-here drug was released and absorbed over 
a period of 6-8 hour and maintain substantial plasma concentration in Parkinson's patients.  
5. Cytotech- containing misoprostol, a synthetic prostaglandin-E1 analog, for prevention of 
gastric ulcers caused by NSAID´s. As it provides high concentration of drug within gastric 
mucosa, it is used to eradicate pylori.   
6. 5-Flurouracil has been successfully evaluated in patients with stomach neoplasm.   
7. Developing HBS dosage form for Tacrine provides a better delivery system and reduces its GI 
side effects in Alzheimer's patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
5 Hypertension:
 
Hypertension (HTN) or high blood pressure, sometimes called arterial hypertension, is 
a chronic medical condition in which the blood pressure in the arteries is elevated. Blood 
pressure involves two measurements, systolic and diastolic, which depend on whether the heart 
muscle is contracting (systole) or relaxed between beats (diastole). Normal blood pressure at rest 
is within the range of 100-140mmHg systolic (top reading) and 60-90mmHg diastolic (bottom 
reading). High blood pressure is said to be present if it is persistently at or above 140/90 mmHg. 
 
Hypertension is classified as either primary (essential) hypertension or secondary hypertension; 
about 90–95% of cases are categorized as "primary hypertension" which means high blood 
pressure with no obvious underlying medical cause. The remaining 5–10% of cases (secondary 
hypertension) are caused by other conditions that affect the kidneys, arteries, heart or endocrine 
system. 
Table no 1: Classification of hypertension 
     
 
 
 
 
 
 
 
 
Signs and symptoms: 
Hypertension is rarely accompanied by any symptoms, and its identification is usually 
through screening, or when seeking healthcare for an unrelated problem. A proportion of people 
with high blood pressure reports headaches (particularly at the back of the head and in the 
morning), as well as lightheadedness, vertigo, tinnitus (buzzing or hissing in the ears), altered 
vision or fainting episodes. 
On physical examination, hypertension may be suspected on the basis of the presence 
of hypertensive retinopathy detected by examination of the optic fundus found in the back of the 
eye using ophthalmoscopy.   
Classification 
Systolic pressure Diastolic pressure 
mm Hg KPa MmHg KPa 
Normal 90–119 12–15.9 60–79 8.0–10.5 
Prehypertension 120–139 16.0–18.5 80–89 10.7–11.9 
Stage 1 hypertension 140–159 18.7–21.2 90–99 12.0–13.2 
Stage 2 hypertension ≥160 ≥21.3 ≥100 ≥13.3 
Isoloated systolic hypertension ≥140 ≥18.7 <90 <12.0 
Secondary hypertension: 
Some additional signs and symptoms may suggest secondary hypertension, i.e. hypertension due 
to an identifiable cause such as kidney diseases or endocrine diseases. For example, truncal 
obesity, glucose intolerance, moon facies, a "buffalo hump" and purple striae suggest Cushing's 
syndrome.   
Hypertensive crises: 
Severely elevated blood pressure (equal to or greater than a systolic 180 or diastolic of 110 
sometime termed malignant or accelerated hypertension) is referred to as a "hypertensive crisis", 
as blood pressures above these levels are known to confer a high risk of complications. People 
with blood pressures in this range may have no symptoms, but are more likely to report 
headaches (22% of cases) and dizziness than the general population. Other symptoms 
accompanying a hypertensive crisis may include visual deterioration or breathlessness due to 
heart failure or a general feeling of malaise due to renal failure.   
In pregnancy 
Hypertension occurs in approximately 8-10% of pregnancies.
 
Most women with hypertension in 
pregnancy have pre-existing primary hypertension, but high blood pressure in pregnancy may be 
the first sign of  pre-eclampsia, a serious condition of the second half of pregnancy 
and puerperium. Pre-eclampsia is characterised by increased blood pressure and the presence 
of protein in the urine.   
In infants and children: 
Failure to thrive, seizures, irritability, lack of energy, and difficulty breathing
 
 can be 
associated with hypertension in neonates and young infants. In older infants and children, 
hypertension can cause headache, unexplained  irritability, fatigue, failure to thrive, blurred     
vision, nosebleeds, and facial paralysis.        
Complications: 
Hypertension is the most important preventable risk factor for premature death worldwide. It 
increases the risk of ischemic heart disease
 
strokes,  peripheral vascular disease, and other 
cardiovascular diseases, including heart failure, aortic aneurysms, diffuse atherosclerosis, and 
pulmonary.  Hypertension is also a risk factor for cognitive impairment and dementia, 
and chronic kidney disease. Other complications include: 
 Hyperten sive retinopathy. 
 Hypertensive nephropathy. 
Cause: 
Primary hypertension 
Primary (essential) hypertension is the most common form of hypertension, accounting for 90–
95% of all cases of hypertension.  Hypertension results from a complex interaction of genes and 
environmental factors. Numerous common genes with small effects on blood pressure have been 
identified as well as some rare genes with large effects on blood pressure but the genetic basis of 
hypertension is still poorly understood. Several environmental factors influence blood pressure. 
Lifestyle factors that lower blood pressure, include reduced dietary salt intake,  increased 
consumption of fruits and low fat products (Dietary Approaches to Stop Hypertension (DASH 
diet)), exercise,  weight loss and reduced alcohol intake.  
Secondary hypertension 
Secondary hypertension results from an identifiable cause. Renal disease is the most common 
secondary cause of hypertension.  
Hypertension can also be caused by endocrine conditions, such as Cushing's 
syndrome, hyperthyroidism, hypothyroidism, acromegaly, Conn'ssyndrome or hyperaldosteronis
m hyperparathyroidism and pheochromocytoma.  
Pathophysiology: 
In most people with established essential (primary) hypertension, increased resistance to blood 
flow (total peripheral resistance) accounting for the high pressure while cardiac outpu  tremains 
normal.  
Pulse pressure (the difference between systolic and diastolic blood pressure) is frequently 
increased in older people with hypertension. This can mean that systolic pressure is abnormally 
high, but diastolic pressure may be normal or low a condition termed isolated systolic 
hypertension. The high pulse pressure in elderly people with hypertension or isolated systolic 
hypertension is explained by increased arterial stiffness, which typically accompanies aging and 
may be exacerbated by high blood pressure.  
Many mechanisms have been proposed to account for the rise in peripheral resistance in  
hypertension. Most evidence implicates either: 
 Disturbances in renal salt and water handling, particularly abnormalities in the 
intrarenal renin-angiotensin system and/or 
 Abnormalities of the sympathetic nervous system 
These mechanisms are not mutually exclusive and it is likely that both contribute to some 
extent in most cases of essential hypertension. It has also been suggested that dysfunction and 
vascular inflammation may also contribute to increased peripheral resistance and vascular 
damage in hypertension.  
Diagnosis 
 
Table no 2: Typical tests performed in hypertension 
Renal 
Microscopic urinalysis, proteinuria, serum BUN (blood urea 
nitrogen) and/or creatinine 
Endocrine Serum sodium, potassium, calcium, TSH (thyroid-stimulating hormone). 
Metabolic Fasting blood glucose, total cholesterol, HDL and LDL cholesterol, triglycerides 
Other Hematocrit, electrocardiogram, and chest radiograph 
 
Prevention: 
For the primary prevention of hypertension: 
 Maintain normal body weight for adults (e.g. body mass index 20–25 kg/m2). 
 Reduce dietary sodium intake to <100 mmol/ day (<6 g of sodium chloride or <2.4 g of 
sodium per day). 
 Engage in regular aerobic physical activity such as brisk walking (≥30 min per day, most 
days of the week). 
 Limit alcohol consumption to not more than 3 units/day in men and not more than 2 
units/day in women. 
 Consume a diet rich in fruit and vegetables (e.g. at least five portions per day). 
Management: 
Lifestyle modifications 
The first line of treatment for hypertension is identical to the recommended preventative lifestyle 
changes
 
and includes: dietary changes physical exercise, and weight loss.  
Medications 
Several classes of medications, collectively referred to as antihypertensive drugs, are currently 
available for treating hypertension.  
(The best first line agent is disputed. The Cochranes collaboration, World Health 
Organization and the United States guidelines supports low dose thiazide-based diuretic as first 
line treatment.)   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
AIM AND OBJECTIVE 
 
 AIM AND OBJECTIVES 
 
Losartan Potassium is an angiotensin-receptor blocker (ARB) that may be used alone or 
with other agents to treat hypertension. The aim of study is to formulate and evaluate of 
sustained release floating tablet of losartan potassium .To study the effect of polymers on the 
release of Losartan potassium, different polymers are used to attain floating sustained drug 
release and give maximum therapeutic  effect for prolonged period of time when taken orally, to 
design a formulation of solid dosage of Losartan potassium tablets with better stability of high 
product quality. 
 
The objectives of the present work include:  
1. Drug-polymer interaction studies.  
2. Preparation of Losartan Potassium sustained release floating tablets using different polymers 
by direct compression technique. 
3. Evaluation of floating tablets for pre and post compression parameters.  
4. Physical parameters like hardness, friability, weight variation, drug content uniformity. 
5. In-Vitro evaluation of sustained release tablets for the release characteristics.  
6. To  carry out stability  studies for selected formulation as per ICH guidelines. 
 
 
  
 
 
 
 
 
 
                               PLAN OF WORK 
The plan of the research work has been scheduled as: 
1.API and excipients characterization to prepare solid oral dosage form of  losartan potassium.  
2.preformulation studies: 
 compatability studies. 
 solubility.  
 Angle of repose. 
 Bulk density. 
 Tapped density. 
 Compressibility index. 
 Hausner  ratio. 
3.Development of sustained released  floating  Tablets by direct compression method. 
4.Evaluation of the formulated tablets for their physio  chemical characteristics  such as: 
  Hardness. 
  Thickness. 
  Friability. 
  weight variation. 
   Floating log time. 
  Content uniformity. 
5.In- vitro dissolution study of the prepared  tablets of  Losartan  potassium. 
6.stability studies. 
 
 
 
  DRUG PROFILE 
Description: 
Losartan is an angiotensin-receptor blocker (ARB) that may be used alone or with other    
agents to treat hypertension.  
Categories: 
• Antihypertensive Agents. 
• Angiotensin II Receptor Antagonists. 
• Antiarrhythmic Agents. 
• Angiotensin II Type 1 Receptor Blockers. 
• Anti-Arrhythmia Agents. 
                            Structure of  Losartan Potassium 
 
           Molecular Formula: C22H23ClN6O•K ½C4H404 
Chemical Name: 2 - Butyl - 4 - chloro - 1 - [[2′ - (1H - tetrazol - 5 - yl)[1,1′ - biphenyl] - 4 - yl] 
- methyl] - 1H - imidazole - 5 - methanol monopotassium salt 
State: solid 
Melting point: 183.5-184.5 
o
C 
 Experimental properties : 
 Table no:3 
 
PROPERTY VALUE 
WATER 
SOLUBILITY 
 
0.82mg/L 
 
Log p 
 
6.1 
 
 
                                           
Molecular weight: Average: 422.911g/mol 
Pharmacology: 
Indications 
May be used as a first line agent to treat uncomplicated hypertension, isolated systolic 
hypertension and left ventricular hypertrophy. May be used as a first line agent to delay 
progression of diabetic nephropathy. Losartan may be also used as a second line agent in the 
treatment of congestive heart failure, systolic dysfunction, myocardial infarction and coronary 
artery disease in those intolerant of ACE inhibitors. 
Pharmacodynamics 
Losartan is the first of a class of antihypertensive agents called angiotensin II receptor blockers 
(ARBs). Losartan and its longer acting active metabolite, E-3174, are specific and selective type-
1 angiotensin II receptor (AT1) antagonists which block the blood pressure increasing effects 
angiotensin II via the renin-angiotensin-aldosterone system (RAAS). RAAS is a homeostatic 
mechanism for regulating hemodynamics, water and electrolyte balance. During sympathetic 
stimulation or when renal blood pressure or blood flow is reduced, renin is released from 
granular cells of the juxtaglomerular apparatus in the kidneys. Renin cleaves circulating 
angiotensinogen to angiotensin I, which is cleaved by angiotensin converting enzyme (ACE) to 
angiotensin II. Angiotensin II increases blood pressure by increasing total peripheral resistance, 
increasing sodium and water reabsorption in the kidneys via aldosterone secretion, and altering 
cardiovascular structure. Angiotensin II binds to two receptors: AT1 and type-2 angiotensin II 
receptor (AT2). AT1 is a G-protein coupled receptor (GPCR) that mediates the vasoconstrictive 
and aldosterone-secreting effects of angiotensin II. Studies performed in recent years suggest that 
AT2 antagonizes AT1-mediated effects and directly affects long-term blood pressure control by 
inducing vasorelaxation and increasing urinary sodium excretion. Angiotensin receptor blockers 
(ARBs) are non-peptide competitive inhibitors of AT1. ARBs block the ability of angiotensin II 
to stimulate pressor and cell proliferative effects. Unlike ACE inhibitors, ARBs do not affect 
bradykinin-induced vasodilation. The overall effect of ARBs is a decrease in blood pressure. 
Mechanism of action: 
Losartan competitively inhibits the binding of angiotensin II to AT1 in many tissues including 
vascular smooth muscle and the adrenal glands. Losartan is metabolized to its active metabolite, 
E-3174, which is 10 to 40 times more potent than losartan and acts as a non-competitive AT1 
antagonist. Inhibition of angiotensin II binding to AT1 inhibits its AT1-mediated 
vasoconstrictive and aldosterone-secreting effects and results in decreased vascular resistance 
and blood pressure. Losartan is 1,000 times more selective for AT1 than AT2. Inhibition of 
aldosterone secretion may increase sodium and water excretion while decreasing potassium 
excretion. Losartan is effective for reducing blood pressure and may be used to treat essential 
hypertension, left ventricular hypertrophy and diabetic nephropathy. 
Absorption: 
Well absorbed, the systemic bioavailability of losartan is approximately 33%. 
Volume of distribution: 
 34 L [losartan] 
 12 L [active metabolite] 
Protien binding: 99.7%, primarily to albumin. 
Metabolism: 
Hepatic: Losartan is metabolized to a 5-carboxylic acid derivative (E-3174) via an aldehyde 
intermediate (E-3179) primarily by cytochrome P450 (CYP) 2C9 and CYP3A4. E-3174 is an 
active metabolite with 10- to 40-fold higher potency than its parent compound, losartan. 
Approxiamtely 14% of losartan is converted to E-3174; however, the AUC of E-3174 was found 
to be 4- to 8-fold higher than losartan and E-3174 is considered the main contributor to the 
pharmacologic effects of this medication. 
Route of elimination: 
After single doses of losartan administered orally, about 4% of the dose is excreted unchanged in 
the urine and about 6% is excreted in urine as active metabolite. Biliary excretion contributes to 
the elimination of losartan and its metabolites. 
Half life: 
The terminal t1/2 of losartan is 2 hours and that of E-3174 is 6-9 hours. 
Clearence: 
600 ml/min [Healthy volunteers after IV administration] 
Renal cl=56 ±  23 ml/min [Hypertensive adults given 50 mg once daily for 7 days] 
Renal cl=53 ± 33 ml/min [Hypertensive children (6-16 years old) given 0.7 mg/kg once daily for 
7 days]  
Toxicity:
 14
  
Hypotension and tachycardia; Bradycardia could occur from parasympathetic (vagal) 
stimulation, LD50= 1000 mg/kg (orally in rat). 
 
 
 
 
 
 
 
 
 
 
 
                                               EXCIPIENT PROFILE   
MICROCRYSTALLINE CELLULOSE
35 
Nonproprietary NamesBP:  
 JP:  Microcrystalline cellulose. 
 Microcrystalline cellulose. 
 PhEur: Cellulosum microcsristallinum. 
 USPNF: Microcrystalline cellulose. 
Synonyms:  
 BP:Microcrystalline cellulose.  
 JP: Microcrystalline cellulose. 
 PhEur: Cellulosum microcristallinum.  
 USPNF: Microcrystalline cellulose. 
Functional Category:  
 Adsorbent; suspending agent; tablet and capsule diluent; tablet disintegrant. 
Description:  
 Microcrystalline cellulose is purified, partially depolymerized cellulose that occurs as a 
 white, odorless, tasteless, crystalline powder composed of porous particles. It is 
 commercially available in different particle sizes and moisture grades that have different 
 properties and applications. 
Typical Properties:  
 Angle of repose: 49
0
 for Ceolus KG; 34.4
0
 for Emcocel 90M. 
 Density (bulk): 0.337 g/cm
3
; 0.32 g/cm
3
 for Avicel PH-101; 0.29 g/cm
3
 for Emcocel 
 90M; 0.29 g/cm
3
 for VivaPur 101. 
 Density (tapped): 0.478 g/cm
3
; 0.45 g/cm
3
 for Avicel PH-101; 0.35 g/cm
3
 for Emcocel 
 90M. 
 Density (true): 1.512–1.668 g/cm3 
 Flowability: 1.41 g/s for Emcocel 90M. 
Melting point: chars at 260–2700C. 
Moisture content: typically less than 5% w/w. However, different grades may contain varying 
 amounts of water. Microcrystalline cellulose is hygroscopic. 
Applications:  
 Microcrystalline cellulose is widely used in pharmaceuticals, primarily as a 
 binder/diluent in oral tablet and capsule formulations where it is used in both wet-
 granulation and direct-compression processes. In addition to its use as a binder/diluent, 
 microcrystalline cellulose also has some lubricant and disintegrant properties that make it 
 useful in tableting. Microcrystalline cellulose is also used in cosmetics and food products. 
 Magnesium stearate
36 
Non proprietary names: 
 
 
 BP: Magnesium stearate 
 
 JP: Magnesium stearate 
 
 PhEur: Magnesii stearas 
 
 USPNF: Magnesium stearate 
 
synonyms: 
 Magnesium octadecanoate; octadecanoic acid, magnesium salt; stearic acid, magnesium 
 salt. 
Chemical Name and CAS Registry Number:   
 Octadecanoic acid magnesium salt [557-04-0] 
 Empirical Formula and Molecular Weight: 
  C36H70MgO4 591.34 
 The USPNF 23 describes magnesium stearate as a compound of magnesium with a 
 mixture of solid organic acids that consists chiefly of variable proportions of magnesium 
 stearate and magnesium palmitate (C32H62MgO4). The PhEur 2005 describes magnesium 
 stearate as a mixture of magnesium salts of different fatty acids consisting mainly of 
 stearic acid and palmitic acid and in minor proportions other fatty acids. 
Structural Formula:   
 [CH3 (CH2)16COO]2Mg 
 Functional Category 
 Tablet and capsule lubricant. 
Applications in Pharmaceutical Formulation or Technology: 
Magnesium stearate is widely used in cosmetics, foods, and pharmaceutical formulations. It is 
primarily used as a lubricant in capsule and tablet manufacture at concentrations between 0.25% 
and 5.0% w/w. It is also used in barrier creams
43 
 
 
 Talc:
37 
Synonyms:  
 Altalc; E553b; hydrous magnesium calcium silicate; hydrous magnesium silicate; Luzenac 
 Pharma; magnesium hydrogen metasilicate; MagsilOsmanthus; Magsil Star; powdered talc; 
 purified French chalk; Purtalc; soapstone; steatite; Superiore. 
Chemical Name: Talc 
Functional Category:  
Anti-caking agent;glidant; diluent andlubricant. 
Description:  
Talc is a very fine, white to greyish-white, odourless, impalpable, unctuous, crystalline powder.  
Typical Properties:  
 Specific gravity: 2.7–2.8 
 Specific surface area: 2.41–2.42 m2/g 
Solubility:  
 It is practically insoluble in dilute acids, alkalis, organic solvents and water. 
Applications:  
 Talc is widely used in oral solid dosage formulations as a lubricant and diluents. It is widely 
 used as a dissolution retardant in the development of controlled-release products. It is also 
 used as an adsorbant. In topical preparations, talc is used as a dusting powder. Talc is 
 additionally used to clarify liquids and is also used in cosmetics and food products. 
  
Stability and Storage Conditions:  
 Talc is a stable material and may be sterilized by heating at 160
o
C for not less than 1 hour. 
 Talc should be stored in a well-closed container in a cool, dry place. 
 Incompatibilities: It is incompatible with quaternary ammonium compounds. 
Safety:  
 Talc is regarded as an essentially nontoxic material. Inhalation of talc causes irritation 
 and may cause severe respiratory distress in infants. 
 
SODIUM BICARBONATE:
 38
 
Nonproprietary Names: 
 • BP : Sodium bicarbonate 
 • JP : Sodium bicarbonate 
 • PhEur : Natrii hydrogenocarbonas 
 • USP : Sodium bicarbonate 
Synonyms: 
 Baking soda; E500; Effer-Soda; monosodium carbonate; Sal de Vichy; sodium acid 
 carbonate; sodium hydrogen carbonate. 
Chemical Name and CAS Registry Number:  
 Carbonic acid monosodium salt [144- 55-8] 
Empirical Formula and Molecular Weight: NaHCO3 84.01 
Functional Category: Alkalizing agent; therapeutic agent. 
Applications: Sodium bicarbonate is generally used in pharmaceutical formulations as a source 
 of carbon dioxide in effervescent tablets and granules. It is also widely used to produce or 
 maintain an alkaline pH in a preparation. 
 Tablets may also be prepared with Sodium bicarbonate alone since the acid of gastric fluid is 
sufficient to cause effervescence and disintegration. Sodium bicarbonate is also used in tablet 
formulations to buffer drug molecules that are weak acids, thereby increasing the rate of tablet 
dissolution and reducing gastric irritation. The effects of tablet binders, such as polyethylene 
glycols, Microcrystalline cellulose, silicified Microcrystalline cellulose, pregelatinized starch, 
and povidone, on the physical and mechanical properties of Sodium bicarbonate tablets have also 
been investigated. Additionally, Sodium bicarbonate is used in solutions as a buffering agent for 
Erythromycin, Lidocaine,  local anesthetic solutions,  and total parenteral nutrition solutions.  In 
some parenteral formulations, e.g., in Niacin parenteral formulation, Sodium bicarbonate is used 
to produce a sodium salt of the active ingredient that has enhanced solubility. Sodium 
bicarbonate has also been used as a freeze-drying stabilizer and in toothpastes. Recently, Sodium 
bicarbonate has been used as a gas-forming agent in alginate raft system  and in floating, 
controlled-release oral dosage forms of Furosemide  and Cisapride Tablet formulations 
containing Sodium bicarbonate have been shown to increase the absorption of Paracetamol, and 
improve the stability of Levothyroxine. Sodium bicarbonate is used in food products as an alkali 
or as a leavening agent, e.g. baking soda. 
                                 Table no 4:  Uses of sodium bicarbonate 
Use Concentration (%) 
Buffer in tablets 10-40 
Effervescent tablets 25-50 
Isotonic injection/infusion 1.39 
 
Use Concentration (%) Buffer in tablets 10–40 Effervescent tablets 25–50 Isotonic 
injection/infusion 1.39 
Description: 
 Sodium bicarbonate occurs as an odorless, white, crystalline powder with a saline, slightly 
alkaline taste. The crystal structure is monoclinic prisms. Grades with different particle sizes, 
from a fine powder to free-flowing uniform granules, are commercially available. 
Typical Properties: 
 Acidity/alkalinity:  pH = 8.3 for a freshly prepared 0.1 M aqueous solution at 25°C; alkalinity 
increases on standing, agitation, or heating. 
 Density (bulk):  0.869 g/cm3 
 Density (tapped):  1.369 g/cm3 
 Density (true):  2.173 g/cm3 
 Freezing point depression: 0.381°C (1% w/v solution) 
 Melting point:  270°C (with decomposition) 
 Moisture content: below 80% relative humidity, the moisture content is less than 1% w/w. 
Above 85% relative humidity, sodium bicarbonate rapidly absorbs excessive amounts of water 
and may start to decompose with loss of carbon dioxide. 
 Osmolarity:  1.39% w/v aqueous solution is isoosmotic with serum. 
 Refractive index: n20 D = 1.3344 (1% w/v aqueous solution) 
  
Solubility: 
                         Table no 5: Solubility of sodium bicarbonate. 
Solvent Solubility At 200C unless otherwise stated 
Ethanol(95%) Practically insoluble 
Ether Practically insoluble 
Water 1 in 4 at 1000C 
 1 in 10 at 250C 
 1 in 12 at 180C 
               
Solvent Solubility at 20°C unless otherwise stated Ethanol (95%) Practically insoluble Ether 
Practically insoluble 1 in 11 1 in 4 at 100°Ca 1 in 10 at 25°C Water 1 in 12 at 18°C 
Stability and Storage Conditions: 
 When heated to about 50°C, Sodium bicarbonate begins to dissociate into carbon dioxide, 
sodium carbonate, and water; on heating to 250–300°C, for a short time, Sodium bicarbonate is 
completely converted into anhydrous sodium carbonate. The effects of relative humidity and 
temperature on the moisture sorption and stability of Sodium bicarbonate powder have been 
investigated. Sodium bicarbonate powder is stable below 76% relative humidity at 25°C and 
below 48% relative humidity at 40°C.At 54% relative humidity, the degree of pyrolytic 
decarboxylation of Sodium bicarbonate should not exceed 4.5% in order to avoid detrimental 
effects on stability.At ambient temperatures, aqueous solutions slowly decompose with partial 
conversion into the carbonate; the decomposition is accelerated by agitation or heat. Aqueous 
solutions of Sodium bicarbonate may be sterilized by filtration or autoclaving. To minimize 
decomposition of Sodium bicarbonate by decarboxylation on autoclaving, carbon dioxide is 
passed through the solution in its final container, which is then hermetically sealed and 
autoclaved. The sealed container should not be opened for at least 2 hours after it has returned to 
ambient temperature, to allow time for the complete reformation of the bicarbonate from the 
carbonate produced during the heating process.Sodium bicarbonate is stable in dry air but slowly 
decomposes in moist air and should therefore be stored in a well-closed container in a cool, dry 
place. 
Incompatibilities: 
 Sodium bicarbonate reacts with acids, acidic salts, and many alkaloidal salts, with the 
evolution of carbon dioxide. Sodium bicarbonate can also intensify the darkening of salicylates. 
In powder mixtures, atmospheric moisture or water of crystallization from another ingredient is 
sufficient for Sodium bicarbonate to react with compounds such as boric acid or alum. In liquid 
mixtures containing bismuth subnitrate, Sodium bicarbonate reacts with the acid formed by 
hydrolysis of the bismuth salt. In solution, Sodium bicarbonate has been reported to be 
incompatible with many drug substances such as Ciprofloxacin, Amiodarone, Nicardipine, and 
Levofloxacin. 
Safety: 
 Sodium bicarbonate is used in a number of pharmaceutical formulations including injections 
and ophthalmic, otic, topical, and oral preparations. Sodium bicarbonate is metabolized to the 
sodium cation, which is eliminated from the body by renal excretion, and the bicarbonate anion, 
which becomes part of the body’s bicarbonate store. Any carbon dioxide formed is eliminated 
via the lungs. Administration of excessive amounts of Sodium bicarbonate may thus disturb the 
body’s electrolyte balance, leading to metabolic alkalosis. When used as an excipient, Sodium 
bicarbonate is generally regarded as an essentially nontoxic and nonirritant material. LD50 
(mouse, oral) : 3.36 g/kg LD50 (rat, oral) : 4.22 g/kg Handling Precautions Observe normal 
precautions appropriate to the circumstances and quantity of material handled. Eye protection 
and gloves are recommended. 
Regulatory Status: 
GRAS listed. Accepted for use as a food additive in Europe. Included in the FDA Inactive 
Ingredients Guide (injections; ophthalmic preparations; oral capsules, solutions, and tablets). 
Included in parenteral (intravenous infusions and injections) and nonparenteral medicines (ear 
drops, eye lotions, oral capsules, chewable tablets, effervescent powders, effervescent tablets, 
granules, tablets, suppositories and suspensions) licensed in the UK 
 
CITRIC ACID : 
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Nonproprietary Names  
 BP: Citric Acid Monohydrate  
 JP: Citric Acid Hydrate  
 PhEur: Citric Acid Monohydrate  
 USP: Citric Acid Monohydra   
   
SYNONYMS: 
 Acidum citricum monohydricum; E330; 2-hydroxypropane-1,2,3-  
 tricarboxylic acid monohydrate.  
CHEMICAL NAME:  
 2-Hydroxy-1,2,3-propanetricarboxylic acid   
 4 Empirical Formula and Molecular Weight  
 C6H8O7_H2O 210.14  
FUNCTIONAL CATEGORY : 
 Acidifying agent; antioxidant; buffering agent; chelating agent;  
 flavor enhancer; preservative.  
 APPLICATIONS : 
 Citric acid (as either the monohydrate or anhydrous material) is widely used in 
pharmaceutical formulations and food products, primarily to adjust the pH of solutions. It has 
also been used experimentally to adjust the pH of tablet matrices in enteric-coated formulations 
for colon-specific drug delivery.(1) Citric acid monohydrate is used in the preparation of 
effervescent granules, while anhydrous citric acid is widely used in the preparation of 
effervescent tablets.(2–4) Citric acid has also been shown to improve the stability of spray-dried 
insulin powder in inhalation formulations. In food products, citric acid is used as a flavor 
enhancer for itstart, acidic taste. Citric acid monohydrate is used as a sequestering agent and 
antioxidant synergist; see Table I. It is also a componentof anticoagulant citrate solutions. 
Therapeutically, preparations containing citric acid have been used to dissolve renal cal. 
 
HYDROXY PROPYL METHYL CELLOLOSE:
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Synonyms    : Benecel, HPMC, Methocel. ,Hypromellose 
              
Chemical Name   : Cellulose Hydroxy  propyly methyl ether 
 
Empirical formula   : CH3 CH2 (OH) CH3 
 
Description    : white or creamy white fibrous or granular,  
      odorless, tasteless. 
 
Melting point    : Browns at 190-200
 o
C  Chars at 225-230
 o
C 
 
Stability    : Stable between pH 3-11. 
Applications  : To retard the release of drugs from a matrix in  
   tablets and capsules. 
   Also used as binder and in tablet coating. 
Functional Category   : Bioadhesive material; coating agent; controlled- 
release agent; dispersing agent; dissolution 
enhancer; emulsifying agent; emulsion stabilizer; 
extended-release agent; film-forming agent; 
foaming agent; granulation aid; modified release 
agent; mucoadhesive; release-modifying agent; 
solubilizing agent; stabilizing agent; suspending 
agent; sustained-release agent; tablet binder; 
thickening agent; viscosity-increasing agent. 
 
Applications    : Hypromellose is widely used in oral,  
ophthalmic, nasal, and topical pharmaceutical 
formulations. In oral products, hypromellose is 
primarily used as a tablet binder, in film coating, 
and as a matrix for use in extended release tablet 
formulations.  High-viscosity grades may be used to 
retard the release of drugs from a matrix in tablets 
and capsules. Hypromellose is also used in liquid 
oral dosage forms as a suspending and/or thickening 
agent. 
 
 
 LITERATURE REVIEW 
1Nalle Suhas et al.,(2009)
15
 prepared design and evaluation of controlled release Nateglinide 
tablets using Hydrophilic polymer formulated by using polymers such as HPMC, MC and Na 
CMC as release retardants. It was observed that the type of polymer and its concentration has 
influenced the drug release from matrix tablets.
 
2 Mukesh C. Gohel et al.,(2009)
16
 concluded that it was possible to fabricate modified release 
tablets of Metoprolol Succinate ER tablets Using HPMC K100M and Xanthan gum. The 
combination of matrixing agents namely xanthan gum and HPMC K100M overcomes 
disadvantages of each polymer. The initial drug burst release was controlled by quick gelation of 
Xanthan gum where as subsequent drug release and matrix integrity were maintained by firm gel 
of HPMC K 100M. The drug release was found to be dependent on the amount and type of 
matrixing agent.
 
3 N.N.Rajendran et al., (2009)
17
conclusively stated that development of extended release 
formulation of hydrophilic drugs does not necessitate the inclusion of hydrophobic polymers to 
hydrophilic polymers and the desired extended release of hydrophilic drugs is also viable with 
hydrophilic polymer alone.
 
4 Antesh K Jha et al., (2009)
18
concluded that the hydrophilic matrix of HPMC alone could not 
control the Metoprolol Succinate release effectively for 16 hours and the matrix tablets prepared 
with HPMC and a granulating agent of a hydrophobic polymer was a better system for once daily 
sustained release of a highly water soluble drugs like Metoprolol Succinate. 
5 R Enayatifard et al., (2009)
19
demonstrated that HPMC and EC could slow down the release 
profile of diltiazem HCl from their matrices. Incorporation of EC in HPMC matrix tablets was 
found to control drug release
.
 
6 Zafar Iqbal et al., (2010)
20
prepared and evaluated matrix tablets of Diclofenac Sodium using 
PVP K90 and natural polymers and concluded that PVP K90 and gum at the drug: polymer ratio 
1:3 sustained the release of the drug for about 12 hours. The addition of the buffers increase the 
initial release of the diclofenac from the dosage form however, drug release was sustained for 
about 10 hours. The combination of PVP K90 and natural gum also sustained the release of the 
diclofenac sodium for about 12 h however, the best similarity and differential factors were 
obtained with the combination of PVP K90 and gum tragacanth.  
7 Madhusudhan pogula et al., (2010)
21
concluded that the use of microcrystalline cellulose one 
can achieve the tablets with good hardness and also concluded that HPMC K 100 shows better 
drug control compared to HPMC E 4 M.
 
 8 Prajapati B. G. et al.,(2010)
22
 prepared once daily sustained release matrix tablets of 
Losartan Potassium and concluded that HPMC alone could not control the Losartan Potassium 
release effectively for 24 hrs. It was evident from the results that a matrix tablet prepared with 
hydrophilic polymer and hydrophobic polymer was a better system for once daily sustained 
release of a highly water soluble drug like Losartan Potassium. 
9 Marina Koland et al.,(2010)
23
 prepared mucoadhesive films of Losartan Potassium for buccal 
delivery using HPMC and retardent polymers Ethyl cellulose or Eudragit RS 100 and concluded 
that it was possible to formulate mucoadhesive films of Losartan Potassium with the intention of 
obtaining better therapeutic efficiency by controlling drug release thereby improving patient 
compliance and increasing bioavailability with decreased dosing and fewer side effects. The use 
of retardent polymers succeeded in delaying drug release, however, higher percentage of these 
tend to decrease the mucoadhesive properties.
 
10 Jaimini Manish et al.,(2011) 
24 
Formulated and evaluated floating effervescent matrix tablets 
of Losartan potassium by using two different grades of methocel K100 and K15 by effervescent 
technique. The effect of citric acid and two different grades of methocel on drug release profile 
and floating property were investigated. A combination of sodium bi carbonate and citric acid 
was found to achieve optimum in vitro buoyancy. It was observed that tablet remain float for 8-
10 hrs. The tablets with high grades of methocel (K100) were found to float for longer duration 
as compared with formulations containing methocel K15M.  
11 Naveen M et al., (2011)
25
 Formulated and evaluated floating tablets of Losartan potassium by 
direct compression method using sodium bicarbonate as the effervescent base. HPMC K4M, 
HPMCK15M, HPMC K100M, were used as polymers to prepare the floating tablets and to study 
the drug release for 12hr in stomach. It was found that the dimensional stability of the 
formulations increase with increasing concentration of the swelling agent.  
12 A.Suman et al.,(2011)
26
 Formulated and evaluated Losartan potassium floating tablets by 
using HPMC K100M, HPMC K15M, HPMC K4M, by effervescent technique. Sodium 
bicarbonate was incorporated as a gas-generating agent. The floating tablets were evaluated for 
physical characteristics, the tablet swelled radially and axially during in vitro buoyancy studies. 
HPMC K100 based matrix tablets showed significantly greater swelling indices compared with 
other batches. The tablets exhibited prolonged drug release profiles while floating over the 
dissolution medium.
 
13 Lingaraj S. Danki et al.,(2011)
27
 Developed and evaluated gastro retentive drug delivery 
system of Losartan Potassium. Formulations were prepared using wet granulation method, 
employing polymers like HPMCK4M, HPMC K15M, carbopol 934P and sodium alginate. 
Sodium bicarbonate and citric acid were used as gas generating agents. Tablets were evaluated 
for polymer interaction studies, swelling index, in vitro floating studies, In vitro drug release and 
short term stability studies. Drug release analysis on the basis of Higuchi-Korsmeyer model 
indicated that diffusion is the predominant mechanism controlling the drug release.
 
14 Parikh Bhavik Anjankumar et al.,(2011)
28
 Formulation and Evaluation of Floating Tablet of 
Atenolol: Functionality of Natural and Synthetic Polymer. The tablets were prepared by direct 
compression. The pre and post compression studies were performed. The release behavior of the natural 
and synthetic polymer was compared. According to obtained data, .natural polymer shows better 
sustained release properties than synthetic polymer. The formulation with guar gum and xanthum gum 
shows better sustained release effect than HPMC different grade.
 
15 R .Vijaya Muthumanikandar et al.,(2011)
29
 Developed and evaluated buccoadhesive tablets 
of Losartan Potassium and concluded that Hardness of the Bioadhesive tablets varied with 
various type and ratio of the Bioadhesive polymers. The difference in the tablets hardness did not 
affect the release of the drug from the hydrophilic matrices which is release by diffusion through 
the gel layer and erosion of this layer and is therefore independent of the dry state of the tablet
.
 
16 Mohd Azharuddin et al., (2011)
30
Formulated and evaluated controlled release matrix tablets 
of antihypertensive drug Losartan Potassium using natural and synthetic hydrophilic polymers 
and concluded that the polymer concentration plays a major role in drug release. As the polymer 
concentration of the tablets increased the drug release was prolonged in a controlled manner.
 
17 Raju G et al., (2012)
31
formulated and evaluated extended release tablets of Venlafaxine HCl 
better drug release control over an extended period time and also concluded that higher viscosity 
grades of polymer concentrations will retard the drug release effectively.
 
18 P Subhash Chandra Bose et al., (2011)
32
formulated and evaluated sustained release tablets 
of Diltiazem HCl using xanthan gum and concluded that xanthan gum, a biodegradable polymer 
can be employed for use as a carrier in developing floating drug delivery systems.
 
19 Ganesan V et al., (2008)
33
formulated and evaluated matrix tablets of Ambroxol HCl using 
guargum and concluded that slow, controlled and complete release of Ambroxol over a period of 
12h was obtained from matrix tablets containing 30% w/w of low-viscosity, 25% w/w medium 
viscosity or 20% w/w high viscosity guar gum respectively.
 
20 Himansu bhusan samal et al., (2011)
34
formulated and evaluated Zidovudine  matrix tablets 
and concluded that stable formulation could be developed by incorporating both hydrophilic and 
hydrophobic polymers in a definite proportion so that sustained release profile is maintained for 
an extended periods of time.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                         
 
METHODOLOGY 
  Materials used 
 Table no 6 : List of materials used  
Sl. no Materials Source 
1 Losartan Potassium 
 Gift sample from Hetero drugs pvt limited, 
hyderabad 
2 HPMC E15  Lara drugs  pvt  limited, hyderabad 
3 HPMC K15 Lara drugs pvt limited, hyderabad 
4 Microcrystalline cellulose Yarrow chem products, Mumbai 
5 Sodium bi Carbonate Lara drugs pvt limited, hyderabad 
6 Citric Acid Lara drugs pvt limited, hyderabad 
7 Talc Molychem, Mumbai. 
8 Magnesium Sterate Lara drugs pvt limited, hyderabad 
Table no 7 : List of instruments used 
Sl. no. Instruments used vendor 
1 Digital balance  Sartorius 
2 Hot air oven Lab india 
3 Monsanto Hardness tester Lab india. 
4 Friabilator, model:EF-2 Lab india 
5 pH meter, model:7007 Lab india 
6 Rotary tablet  punching machine  Elite scientific and equipment, Guntur. 
7 
Dissolusion 
apparatus(USP)Type-II 
Lab india 
8 
UV-Visible spectrophotometer, 
model: SL-164 double beam. 
Lab india 
9 sonicator Pci analytics 
10 Vernier callipers Mitutoyo corporation 
  
11 Bulk density apparatus Lab india 
12 FT-IR spectrophotomer Jasco 
 
 
 
 
 
 
 
 
PRE FORMULATION STUDIES: 
DRUG- EXCIPIENTS IN- COMPATIBILITY STUDIES: 
Drug was mixed with excipients .about 5gms of blend was prepared , which were kept in 10 ml  
white colored glass  vials and packed properly .these vials are exposed  to room temperature and 
40
0
c±2
0
C/75±5% RH. Observations for physical appearance were made at zero weeks to 1 
month, then the samples were  withdrawn for analysis  of appearance.The drug excipients 
interaction was investigated by FT-IR 
FT-IR- SPECTROSCOPY: 
 Drug and excipients compatibility study is done by Fourier Transform Infrared 
Spectroscopy [FTIR]. FT-IR  Spectra were obtained by using an FT-IR Spectroscopy-
(PERKINELMER). The samples (pure drug) was previously ground and mixed throughly with  
KBr,  an infrared  transparent matrix at( sample/KBr) ratio respectively. the  KBr  discs were 
prepared by  the compressing  the powders at a pressure of 5 tons for 5min in a hydraulic press 
(40 scans  were obtained  at a resolution 4cm
-1
 from 4600-300cm
-1
). 
The  compatibility  studies provide the frame work for the drugs  combination with the excipients 
in the fabrication of the  dosage form. The study was carried out to establish that the 
therapeutically active drug  has not  undergone any changes ,after it has been subjected to  
processing steps during  formulation of tablets. 
STANDARD CURVE OF LOSARTAN POTASSIUM
40 
Preparation of 0.1 N  HCL:  
 8.5 ml of concentrated hydrochloric acid was diluted with distilled water and the volume 
was made upto 1000 ml with distilled water. 
Preparation of  Losartan potassium standard stock solution in o.1N HCL: 
 A Standard solution of Losartan Potassium was prepared by dissolving accurately 
weighed 100 mg of Losartan potassium with little quantity of 0.1N HCL solution ,in a 100 ml 
volumetric flask.The volume was  made  up to  100 ml with 0.1N HCL to obtain  a stock solution  
of  1000 mcg/ml .from the above solution several dilutions are made to obtain 50, 75,100, 125, 
150 mcg/ml solutoions. The absorbance of  these drug solutions were estimated at .λmax 234 nm. 
 
 
 
FORMULATION DEVELOPMENT AND EVALUATION 
 The active ingredient i.e. Losartan Potassium and each single polymer (HPMC E15) 
(  HPMCK15) and also mixture of two polymers, filler (MCC), lubricant (Magnesium stearate) 
glidant (Talc) Floting (sodium bi carbonate and citric acid )were blended together by dry mixing 
in a laboratory mixer (polybag) for 10 mins. The mixture was compressed by using 8mm 
standard flat round punch and die set at compression force 4-6 ton.  
8.1 Preparation of tablets by direct compression:   
Direct compression 
 The ideal process from a capital and operational cost basis is direct compression. This is, 
at most, a two-step process involving screening and/or milling and final mixing. An effective 
excipient binder is needed and should have good compression and consolidation properties as a 
dry additive, even at low concentrations (< 30%) in the formulation. Good adhesive properties in 
the dry form are a combination of a rough and porous surface combined with a Vander Waal's 
and/or a hydrophilic bonding mechanism to attach the active ingredient(s) to the excipients. This 
feature is needed to assure good mixing of drug and excipients and to prevent segregation. 
Advantages of direct compression 
1. Economy in labor, time, equipment, operational energy, and space. 
2. Problems due to heat and moisture eliminated. 
3. Greater physical stability provided; hardness and porosity changes less with time   when direct 
compression is broadly compared to wet granulation systems. 
4. Extraction of the drug from the dosage form is not inhibited during the assay procedure 
(polymer binding). 
Disadvantages of direct compression 
1.  Difficulty obtaining dense hard tablets for high-dose drugs. 
2. No homogenous distribution of low-dose drugs due to segregation after blending (content 
uniformity). 
3. Need for assisted feed and pre compressions for some high-dose drugs. 
4. Need for commensurate particle size or particle size distribution between drug and excipients. 
 
 
 Table no 8: Formulation of  Losartan potassium 
Quantity per batch (mg/tab) 
INGREDIENTS F-1 F-2 F-3 F-4 F-5 F-6 
Losartan Potassium 50 50 50 50 50 50 
HPMC(E15) -- -- 200 -- 200 200 
HPMC K( 15) 50 200 -- -- -- -- 
HPMC(E15)+HPMCK( 15) -- -- -- 100+100 -- -- 
Microcrystalline cellulose 201 51 51 51 65 75 
Sodium bi carbonate 30 30 30 30 20 10 
Citric acid 5 5 5 5 5 5 
Talc 7 7 7 7 5 5 
Magnesium  Sterate 7 7 7 7 5 5 
Total weight 350 350 350 350 350 350 
 
PRE-COMPRESSION EVALUATION PARAMETERS 
 Angle of repose: 
 The angle of repose of powder blend was determined by the funnel method. The 
accurately weigh powder blend were taken in the funnel. The height of the funnel was adjusted 
in such a way the tip of the funnel just touched the apex of the powder blend. The powder blend 
was allowed to flow through the funnel freely on to the surface. The diameter of the powder cone 
was measured and angle of repose was calculated using the following equation.                                
                                                      
 
 
 
Where, 
 h and r are the height and radius of the powder cone. 
 
 
 
 Table no 9: Comparison between angle of repose and flow properties
41
 
Angle of repose ( θ ) Flow 
< 25 Excellent 
25 – 30 Good 
30 – 40 Moderate (addition of 0.2% glidant required) 
> 40 Poor 
 
Bulk density:
 
 Both bulk density (BD) and tapped density (TD) was determined. A quantity of 10 gm of 
powder blend from each formula, previously shaken to break any agglomerates formed, was 
introduced in to 50 ml measuring cylinder. After that the initial volume was noted and the 
cylinder was allowed to fall under its own weight on to a hard surface from the height of 2.5 cm at 
second intervals. Tapping was continued until no further change in volume was noted. Bulk 
density(BD)  and Tapped density (TD) were calculated using the following equations. 
    
                          
                              
 
    
                          
                            
 
 
Table no 10: Flowability according to Hausner’s ratio 
Hausner’s ratio Flow character 
1.0-1.11 Excellent 
1.12-1.18 Good 
1.19-1.25 Fair 
1.26-1.34 Passable 
1.35-1.45 Poor 
1.46-1.59 Very poor 
> 1.60 Very, very poor 
 
  
 Compressibility index (Carr’s Index):  
  Compressibility index is an important measure that can be obtained from the bulk and 
tapped densities. In theory, the less compressible a material the more flowable it is. A material 
having values of less than 20% has good flow property.
42,43,44 
 
. 
   
                             
              
     
 
Table no 11:Properties of compressibility index 
 
 
 
 
 
 
 
POST COMPRESSION EVALUATION PARAMETERS
45 
 The tablets were evaluated for in process and finished product quality control tests i.e. 
appearance, dimensions (diameter and thickness), weight variation, hardness, friability, assay, 
and drug content.  
Physical appearance: 
 The general appearance of tablets, its visual identity and overall elegance is essential for 
consumer acceptance. the control of general appearance of tablet involves measurement of 
number of attributes such as tablet size, shape, colour presence or absence of odour, taste, 
surface texture and constituency of any identification of marks. 
Thickness: 
 10 tablets were measured for their and diameter with a vernier caliper. thickness Guage 
average  thickness and diameter were calculated. 
 
% Comp. Index Properties 
5-12 Free flowing 
12-16 Good 
18-21 Fair 
23-35 Poor 
33-38 Very poor 
>40 Extremely poor 
  
 Weight variation:  
 The weight of the tablet being made was routinely determined to ensure that a tablet 
contains the proper amount of drug. The USP weight variation test is done by weighing 20 tablets 
individually, calculating the average weight and comparing the individual weights to the average. 
The tablets met the USP specification that not more than 2 tablets are outside the percentage limits 
and no tablet differs by more than 2 times the percentage limit. USP official limits of percentage 
deviation of tablet are presented in the table. 
Table no 12: Weight variation limits 
S. No. Average weight of tablet (mg) Maximum % difference allowed 
1 130 or less 10 
2 130-324 7.5 
3 >324 5 
 
Tablet hardness: 
  The resistance of tablets to shipping or breakage under conditions of storage, 
transportation and handling before usage depends on its hardness. The hardness of each batch of 
tablet was checked by using Monsanto hardness tester. The hardness was measured in terms of 
kg/cm
2
. 3 tablets were chosen randomly and tested for hardness.  The average hardness of 3 
determinations was recorded. 
Friability: 
  Friability generally refers to loss in weight of tablets in the containers due to removal of 
fines from the tablet surface. Friability generally reflects poor cohesion of tablet ingredients.  
Method 
  10 tablets were weighed and the initial weight of these tablets was recorded and placed in 
Roche friabilator and rotated at the speed of 25 rpm for 100 revolutions.  Then tablets were 
removed from the friabilator, dusted off the fines and again weighed and the weight was recorded. 
           
       
  
     
Where, w1= weight of the tablet before test.                                                                                    .            
  w2 = weight of the tablet after test. 
IN-VITRO BUOYANCY STUDIES: 
 The in vitro buoyancy was determined by floating lag time .The tablets were placed in a 
100 ml beaker containing 0.1N hydrochloric acid. The time required for the tablet to rise  to the 
surface and to  float was determined as floating lag time. The duration of time for which the 
dosage form constantly remained on the surface of medium was determined as the total floating  
time. 
Drug content: 
 twenty tablets were taken, powdered and the powder equivalent to  one dose each was 
transferred  to  a 100 ml  volumetric flask and 0.1N HCL. The solution was filtered and diluted 
suitably  and drug content in the sample was estimated   using  UV-Visible spectrophotometer at 
234 nm. 
IN-VITRO DISSOLUTION STUDIES:
46 
 The In-vitro drug release study was performed  for all the  tablets using USP type II 
dissolution apparatus under the following conditions. 
Dissolution test parameters: 
Medium  :  900 ml of 0.1 N HCL 
Temperature  :  37
0
±0.5
0
c 
RPM  :   50 
Sampling volume  :  5 ml 
Sampling time :  1, 4, 8, 16, 20 hours 
Preparation of 0.1 N HCL: 
 Take 8.5 ml of concentrated hydrochloric acid in a 1000 ml volumetric flask and make up 
the volume. 
 
 Procedure: 
 Tablet was introduced  into dissolution test apparatus and the apparatus was set as 50 rpm 
.5 ml of sample was withdrawn   at  the  predetermined time intervals. samples were analyzed by 
UV spectrophotometer at 234 nm using 0.1 N HCL solution as blank. 
STABILITY STUDIES:
47 
 The purpose of  stability testing  is to  provide evidence on how the quality of a  drug 
substance or drug product varies with time under the influence of a variety  environmental 
factors , such as temperature , humidity etc .the product is subjected to short time studies at 40
0
C 
± 2
0
C / 75%±5%RH for  3months. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                
RESULTS AND DISCUSSION 
    Table no13: DRUG-EXCIPIENTS PHYSICAL  IN COMPATABILITY STUDIES: 
 
 
 
S.NO 
 
 
 
INGREDIENTS 
 
 
 
RATIO 
 
 
DESCRIPTION 
 
INTIAL 
AFTER 1 MONTH AT 
( 400C;75%RH) 
 
       1 
 
LOSARTAN POTASSIUM -API 
 
     1 
 
WHITE TO OFF 
WHITE POWDER 
 
NCC 
 
       2 
 
API±HPMC E15 
 
1:1 
 
WHITE TO OFF 
WHITE POWDER  
 
NCC 
 
      3 
 
API±HPMC K15 
 
1:1 
 
WHITE TO OFF 
WHITE POWDER 
 
NCC 
 
      4 
 
API±MCC 
 
1:1 
 
 OFF WHITE 
POWDER 
 
 
NCC 
 
5 
 
API±SODIUM BI CARBONATE 
 
1:1         
 
WHITE POWDER 
 
NCC 
 
6 
 
API±CITRIC ACID 
 
1:1  
 
 OFF WHITE 
POWDER 
 
NCC 
 
7 
 
API±MAGNESIUM STEARATE 
 
1:1  
 
OFF WHITE 
POWDER 
 
NCC 
 
8 
 
API±TALC 
 
1:1  
 
WHITE TO OFF 
WHITE POWDER 
 
NCC 
  
Fig no 2: FT-IR spectrum of pure drug 
 
Figno3: Pure drug and  HPMCE15 
 
 
  
Fig no4: Pure drug and  HPMC K15 
 
         Fig no 5: Pure drug and MCC 
 
 
  
 
Fig no 6: Pure drug with other excipients 
 
 
  
Table no:14 Absorbances for Calibration curve of Losartan Potassiuum 
 
Sl. no Concentration (mcg/mL) Absorbance 
1 0 0 
2 5O 0.1929 
3 75 0.2744 
4 100 0.3462 
5 125 0.4256 
6 150 0.5110 
 
 
  
 
 
             Fig  no 7: Calibration curve of Losartan Potassiuum 
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Table NO: 15 Data for Angle of repose 
Formulation code 
Angle of repose 
 
F-1 25.260 ± 0.672 
F-2 26.290 ± 0.587 
F-3 26.450 ± 0.652 
F-4 27.040 ± 0.498 
F-5 25.140 ±0.622  
F-6 26.38 ±0.595  
 
 
 
Fig no 8: COMPARISON OF ANGLE OF REPOSE 
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Table no16:Data for bulk density and tapped density 
Formulation code Bulk Density (gm/ml) 
 
 
Tapped Density 
(gm/ml) 
 
F-1 0.5384±0.191 0.5833±0.272 
F-2 0.5599±0.0.281 0.6087±0.293 
F-3 0.6087±0.281 0.6363±0.321 
F-4 0.5384±0.191 0.6363±0.321 
F-5 0.5599±0.221 0.6087±0.293 
F-6 0.6087±0.281 0.6666±0.354 
 
 
 
                             Fig no9: Comparison of bulk density 
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        figno10: comparison of tapped density 
 
 
  
                   fig no:11 comparison of compressibility index 
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Fig no 12:comparison of Hauner
'
s ratio 
  
  Table no17: Data for Hausner’s ratio and Compressibility index: 
Formulation code Hausner’s Ratio Compressibility Index (%) 
F-1 1.0833 7.6923 
F-2 1.0869 8.000 
F-3 1.0454 4.3478 
F-4 1.0400 3.8461 
F-5 1.0869 8.000 
F-6 1.0952 8.6956 
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Evaluation of tests: 
Table no 18: Data for Weight variation 
Formulation code Weight variation 
 
F-1 352.4±4.3 
F-2 351.1±2.9 
F-3 350.5±2.4 
F-4 348.4±2.1 
F-5 353.9±5.9 
F-6 355.4±6.2 
 
 
Fig no 13: comparison of weight variation 
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Table no 19 : Data for Hardness 
Formulation code Hardness test (Kg/cm2) 
Avg ± SD (n=5) 
F-1 4.3 ± 0.24 
F-2 4.2 ± 0.24 
F-3 4.7 ± 0.24 
F-4 5.5 ± 0.24 
F-5 4.3 ± 0.24 
F-6 4.9 ± 0.20 
 
 
 
 Fig no14: Comparison of hardness 
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Table no 20 : Data for Friability 
 
Formulation code Friability (%) 
 
F-1  0.28 
F-2  0.37 
F-3  0.25 
F-4  0.18 
F-5  0.48 
F-6  0.74 
 
 Fig no15:Comparison of friability  
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Table21 : Data for Thickness 
 
Formulation code Thickness(mm) 
 
F-1 3.52±0.03 
F-2 3.51± 0.01 
F-3 3.53± 0.04 
F-4 3.50± 0.01 
F-5 3.52± 0.03 
F-6 3.53± 0.04 
 
Fig no16: comparison of thickness 
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 Table no 22: Data for floating lag time and  total floating time 
Formulation code Floating lag time(sec) Total floating time(hrs) 
F-1 92 12 
F-2 105 16 
F-3 105 16 
F-4 90 16 
F-5 172 17 
F-6 114 16 
 
Fig no17:comparison of floating  lag time 
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Table no 23 :  Data for Drug content uniformity 
Formulation code Drug content (%) 
F-1 95 
F-2 85 
F-3 97 
F-4 100 
F-5 102 
F-6 99 
 
Fig no18:  Comparison of drug content 
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Table no24: DISSOLUTION TABLE FOR F1  
s.no TIME(HRS)  %DRUG RELEASE 
1 1 4.9 
2 4 39.4 
3 8 63.2 
4 16 62.7 
5 20 83.5 
 
 
 Fig no:19 Dissolution profile -F-1 
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   Table no 25 :DISSOLUTION TABLE FOR F2 
  
s.no TIME(HRS)  %DRUG RELEASE 
1 1 6.8 
2 4 34.1 
3 8 54.3 
4 16 65.7 
5 20 93.9 
  
Fig no20:Dissolution profile -F2 
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  Table no:26   Dissolution table for F3  
s.no TIME(HRS)  %DRUG RELEASE 
1 1 3.4 
2 4 39.2 
3 8 58.6 
4 16 71.3 
5 20 93.9 
 
 
Fig no21: Dissolution profile  F-3 
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 Table no 27: DISSOLUTION TABLE FOR F-4  
s.no TIME(HRS)  %DRUG RELEASE 
1 1 14.1 
2 4 58.3 
3 8 55.7 
4 16 60.6 
5 20 92.1 
Fig no22:Dissolution profile F-4 
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                 TABLE NO:28 DISSOLUTION TABLE FOR F5  
s.no TIME(HRS)  %DRUG RELEASE 
1 1 7.7 
2 4 34.1 
3 8 58.6 
4 16 62.9 
5 20 97 
 
Fig no23: Dissolution profile F-5 
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Table no29: DISSOLUTION TABLE FOR F6  
S.N0 TIME(HRS)  %DRUG RELEASE 
1 1 17 
2 4 58.3 
3 8 55.7 
4 16 60.6 
5 20 92.1 
Fig no 24:Dissolution profile F-6 
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Table no:30  Cumulative percentage of   of all the formulation(F1-F6) 
 
FORMULATION 
 
1HR 
 
4HR 
 
8HR 
 
16HR 
 
20HR 
 
F1 
 
4.9 
 
39.4 
 
63.2 
 
62.7 
 
83.5 
 
F2 
 
6.8 
 
34.1 
 
54.3 
 
65.7 
 
93.9 
 
F3 
 
3.4 
 
39.2 
 
58.6 
 
71.3 
 
93.9 
 
F4 
 
14.1 
 
58.1 
 
55.5 
 
60.6 
 
92.1 
 
F5 
 
7.7 
 
34.1 
 
58.6 
 
62.9 
 
97 
 
F6 
 
17 
 
58.3 
 
55.7 
 
60.6 
 
92.1 
 
 
 
 
 
 
 
 
Fig no25:Cumulative percentage of drug release  of all The formulations 
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STABILITY STUDIES: 
Dissolution profile of  Losartan Potassium tablets from formulation F5 
  after  30 days and 90 days at 40±2
0
c/ 75±5% RH 
  
Table no:31 stability studies of the  F5  Formulation  
 
S.NO 
 
TIME(HRS) 
 INTIALDRUG 
RELEASE 
 
30DAYS 
 
90DAYS 
1 1 7.7 7.4 7.1 
2 4 34.1 33.7 33.1 
3 8 58.6 58.1 57.1 
4 16 62.9 62.2 61.9 
5 20 97 96.8 96.75 
 
 
 
 
 
 
 
 
 
  
DISCUSSION: 
The present investigation was undertaken to formulate losartan potassium sustained release 
floating tablets for the treatment of hypertension . Formulations were evaluated for pre and post 
compression parameter. 
The compatibility studies for the drug and excipients used in the formulation  were  carried out 
.The FT-IR spectral analysis showed that there was no change in characteristic peaks of pure 
drug Losartan potassium and excipients which confirmed that the absence of chemical 
interaction between the drug and excipients. . 
 
  6 formulations were formulated by using different proportions of polymers and floating agents. 
All the formulations were prepared by direct compression . The blend of different formulations 
were evaluated  for angle of repose ,bulk density and tapped density , Hausner's ratio, and 
compressibility index. The results showed that all the formulations of powders were within the 
limits and thus it confirmed that the powders have a very good flow property . 
 
 The results of post compression such  as  thickness  , hardness , friability ,weight variation and 
drug content and floating log time for the prepared formulation were within the limits  . 
 
In the formulations F1,F2 ,F4 and f6 f3 ,the polymer ratio is used in much quality and the results 
in less release of drug is seen at the time of dissolution where as the drug coated with less 
polymer show a very good release dissolution release profile rate than other formulations and 
given best  results . 
 
In   the   formulation F5  prepared with HPMC E15 200mg and MCC 65mg in sufficient quantity 
showed maximum (97%) in-vitro drug release at the end of 20 hrs . Although   all the 
formulations shown a good release in-vitro release profiles even more than 90% . 
 
 
The stability study studies has been carried out for the best formulation F5 at 40±2
0
C/75±5% RH 
as per ICH guidelines for three month .Finally the drug is assayed for content uniformity and 
weight variation and cumulative percentage of drug release show no characteristic change .And 
hence prepared formulation found to be stable .  
 
In  the present work efforts have been made to developed Losartan  potassium sustained release 
floating tablets was depend upon polymer and floating agents ratio . The results showed that the 
in vitro drug release depend upon the concentration of polymer and floating agents used .The 
best (f5)  formulation contain sufficient quantity of HPMC E15 and MCC and invitro drug 
release is compared with the other formulations . 
SUMMARY AND CONCLUSION 
 
Losartan potassium tablets  used for the treatment of hypertension. 
 
 Losartan potassium   tablets were successfully   formulated by using different concentration of   
polymers (HPMC E 15, HPMC K15,MCC , MG.STERATE and ,Sodium bicarbonate ,citric acid 
and TALC ) to sustain the drug for a prolonged period of   time . 
 
FTIR study performed for identification and compatability study of drug and exepients  ,  found 
no characteristic change in drug-excipient powder mixture. Hence the excipients were selected 
for the formulation development. 
 
Powder blends were evaluated for tests, such as bulk density, tapped density, compressibility 
index and Hausners ratio before being punched as tablets. 
 
The In-vitro dissolution profiles of   F1 to F6 were found to have different percentage of drug 
release .The percentage of drug   release   is low (83.5) for F1 tablets when compared to other 
formulations .F5 has better percentage drug  release profile with maximum (97%)at the end of 
20
th
 hr  sustained action .The   F5  formulation was fabricated with a very less polymer ratio and 
show a very a good release profile at the end of 
 
2O
th 
hr. 
 
The optimized batch   tablets  , stability studies are carried out for three months ,as per ICH 
guidelines ( 40±2
0
C/RH75±5).Tablets were evaluated for assay and  in-vitro dissolution, but 
 found no significant change during the study period . 
 
 
CONCLUSION  : 
 
It can be concluded that sustained release tablets of Losartan potassium can be performed by 
direct compression method .All the formulas show a very good drug release profiles and shown 
better sustained  action till the end of last hour (20
th
 hrs) .And hence will improve patient 
compliance and increase in bioavailability. 
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